Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 May 20;21(1):578.
doi: 10.1186/s12885-021-08349-8.

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

C van Marcke #  1   2 , N Honoré #  1   2 , A van der Elst #  1   2 , S Beyaert  2 , F Derouane  1   2 , C Dumont  1 , F Aboubakar Nana  3   4 , J F Baurain  1   2 , I Borbath  1   2   5 , P Collard  3   4 , F Cornélis  1   2 , A De Cuyper  1   2 , F P Duhoux  1   2 , B Filleul  1   6 , R Galot  1   2 , M Gizzi  1   7 , F Mazzeo  1   2 , T Pieters  3   4 , E Seront  1   6 , I Sinapi  1   7 , M Van den Eynde  1   2   5 , N Whenham  1   8 , J C Yombi  2   9 , A Scohy  10 , A van Maanen  11 , J P Machiels  12   13
Affiliations
Observational Study

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

C van Marcke et al. BMC Cancer. .

Abstract

Background: The viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk factors, and outcome of severe COVID-19. The safety of systemic anti-cancer therapy in oncology patients with non-severe COVID-19 is an important matter in daily practice.

Methods: ONCOSARS-1 was a single-center, academic observational study. Adult patients with solid tumors treated in the oncology day unit with systemic anti-cancer therapy during the initial phase of the COVID-19 pandemic in Belgium were prospectively included. All patients (n = 363) underwent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) serological testing after the first peak of the pandemic in Belgium. Additionally, 141 of these patients also had a SARS-CoV-2 RT-PCR test during the pandemic. The main objective was to retrospectively determine the safety of systemic cancer treatment, measured by the rate of adverse events according to the Common Terminology Criteria for Adverse Events, in SARS-CoV-2-positive patients compared with SARS-CoV-2-negative patients.

Results: Twenty-two (6%) of the 363 eligible patients were positive for SARS-CoV-2 by RT-PCR and/or serology. Of these, three required transient oxygen supplementation, but none required admission to the intensive care unit. Hematotoxicity was the only adverse event more frequently observed in SARS-CoV-2 -positive patients than in SARS-CoV-2-negative patients: 73% vs 35% (P < 0.001). This association remained significant (odds ratio (OR) 4.1, P = 0.009) even after adjusting for performance status and type of systemic treatment. Hematological adverse events led to more treatment delays for the SARS-CoV-2-positive group: 55% vs 20% (P < 0.001). Median duration of treatment interruption was similar between the two groups: 14 and 11 days, respectively. Febrile neutropenia, infections unrelated to COVID-19, and bleeding events occurred at a low rate in the SARS-CoV-2-positive patients.

Conclusion: Systemic anti-cancer therapy appeared safe in ambulatory oncology patients treated during the COVID-19 pandemic. There were, however, more treatment delays in the SARS-CoV-2-positive population, mainly due to a higher rate of hematological adverse events.

Keywords: Ambulatory; Non-severe COVID-19; Safety; Systemic anti-cancer treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart showing patient enrollment and exclusion
See this image and copyright information in PMC

References

    1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–793. doi: 10.1001/jama.2020.12839. - DOI - PubMed
    1. Triggle CR, Bansal D, Farag EABA, Ding H, Sultan AA. COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. mSphere. 2020;5(3):e00317–e00320. doi: 10.1128/mSphere.00317-20. - DOI - PMC - PubMed
    1. Pelin C, Timothy K, Alison F, Asmita M, Lawrence S, James B, et al. Safety at the time of the COVID-19 pandemic: how to keep our oncology patients and healthcare workers safe. J Natl Compr Canc Netw. 2020;18(5):504–509. doi: 10.6004/jnccn.2020.7572. - DOI - PubMed
    1. Curigliano G, Banerjee S, Cervantes A, Garassino M, Garrido P, Girard N, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO interdisciplinary expert consensus. Ann Oncol. 2020;31(10):1320–1335. doi: 10.1016/j.annonc.2020.07.010. - DOI - PMC - PubMed
    1. ASCO special report : a guide to cancer care delivery during the COVID-19 pandemic. https://www.asco.org/sites/newwww.asco.org/files/content-files/2020-ASCO... Accessed 3 Nov 2020.

Publication types